Aspectos imunogenéticos de doenças neuropediátricas
o papel dos antígenos de histocompatibilidade humanos
DOI:
https://doi.org/10.34024/rnc.2007.v15.8734Palavras-chave:
HLA, Complexo principal de histocompatibilidade, Criança, AdolescenteResumo
Objetivo: Atualizar a associação do sistema de histocompatibilidade humano (HLA) com doenças neuropediátricas e descrever seus possíveis mecanismos patogênicos. Fontes dos dados: Pesquisa bibliográfica através da busca de artigos científicos nos bancos de dados MEDLINE e LILACS no período de 1990 a 2005. Os artigos foram selecionados de forma que abordassem a associação do HLA com doenças neuropediátricas. Percebida a relevância, também foram selecionadas através de busca manual as referências indicadas nos artigos selecionados pelas bases de dados. Síntese dos dados: Esse trabalho se organiza em tópicos, nos quais são discutidos e apresentados prováveis mecanismos pelos quais a estrutura e função das moléculas de histocompatibilidade influenciam o desenvolvimento de enfermidades neurológicas da criança. Conclusão: A associação do sistema HLA com algumas doenças neurológicas da infância está bem estabelecida, a exemplo da miastenia grave. Em outras doenças, contudo, mais estudos são necessários para confirmar dados preliminares sugestivos dessa associação. O estabelecimento de associações de susceptibilidade e proteção mais fortes permitirá o uso do sistema HLA na avaliação do risco individual que o portador de determinado alelo ou haplótipo em particular tem de vir a desenvolver uma doença e assim contribuir para um melhor entendimento da sua patogenia.
Referências
Klein J, Sato A. The HLA System. First of two parts. N Engl J Med 2000; 343(10): 702-709. DOI: https://doi.org/10.1056/NEJM200009073431006
Alves C, Souza T, Veiga S, Alves CA, Toralles MB, Lemaire D. Importância do sistema de histocompatibilidade humano (HLA) em Pediatria. Pediatria (São Paulo) 2005; 27(4): 274-286.
Donadi EA. Aspectos moleculares do complexo principal de histocompatibilidade: como entender a associação entre o sistema HLA e as doenças reumáticas. Rev Bras Reumatol 2001; 41(4): 225-235.
Probst CM, Bompeixe EP. HLA Polymorphism and evaluation of European, African, and Amerindians contribution to the white and mulatto population from Paraná, Brazil. Hum Biol 2000; 72(4): 597-617.
Castro-Cago M. Neurología pediátrica y genética: introducción. Rev Neurol 2002; 35(2): 145-148. DOI: https://doi.org/10.33588/rn.3502.2002121
Almeida SM. O sistema nervoso central é um sítio imunologicamente privilegiado? Rev Bras Neurol 1999;35(4): 81-86.
Bradl M, Hohfeld R. Molecular pathogenesis of neuroinflamation. J Neurol Neurosurg Psychiatr 2003; 74: 1364–1370 DOI: https://doi.org/10.1136/jnnp.74.10.1364
Collawn JF, Benvenistre EN. Regulation of MHC class II expression in the central nervous system. For Immunol 1999; 893-902 DOI: https://doi.org/10.1016/S1286-4579(99)00228-2
Geleijns K, Schreuder GM, Jacobs BC, Sintnicolaas K, van Koningsveld R, Meulstee J, et al. HLA class II alleles are not a general susceptibility factor in Guillain-Barré syndrome. Neurology 2005; 64(1): 44-49. DOI: https://doi.org/10.1212/01.WNL.0000148727.02732.01
Li H, Yuan J, Hao H, Yan Z, Wang S. HLA alleles in patients with Guillain-Barré syndrome. Chin Med J (Engl) 2000; 113(5): 429-432.
Ma JJ, Nishimura M, Mine H, Kuroki S, Nukina M, Ohta M, et al. HLA and T-cell receptor gene polymorphisms in Guillain-Barre syndrome. Neurology 1998; 51(2):379-384. DOI: https://doi.org/10.1212/WNL.51.2.379
Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004; 3(2): 104-110. DOI: https://doi.org/10.1016/S1474-4422(03)00663-X
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000; 343(13): 938-952. DOI: https://doi.org/10.1056/NEJM200009283431307
Hensiek AE, Sawcer SJ, Feakes R, Deans J, Mander A, Akesson E, et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatr 2002; 72(2): 184-187. DOI: https://doi.org/10.1136/jnnp.72.2.184
Dyment DA, Herrera BM, Cader MZ, Willer CJ, Lincoln MR, Sadovnick AD, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet. 2005; 14(14): 2019-2026. DOI: https://doi.org/10.1093/hmg/ddi206
Caballero A, Alves-Leon S, Papais-Alvarenga R, Fernandez O, Navarro G, Alonso A. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians. Tissue Antigens 1999; 54(5): 524-526. DOI: https://doi.org/10.1034/j.1399-0039.1999.540511.x
Lincoln MR, Montpetit A, Cader MZ, Saarela J, Dyment DA, Tiislar M, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005; 37(10): 1108-1112. DOI: https://doi.org/10.1038/ng1647
Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 2001; 357: 2122–2128. DOI: https://doi.org/10.1016/S0140-6736(00)05186-2
Fernández-Mestre MT, Vargas V, Montagnani S, Cotúa M, Ogando V, Layrisse Z. HLA class II and class I polymorphism in Venezuelan patients with myasthenia gravis. Hum Immunol 2004; 65, 54–59. DOI: https://doi.org/10.1016/j.humimm.2003.10.003
Garcıa-Ramos G, Téllez-Zenteno JF, Zapata-Zúñiga M, Yamamoto-Furusho JK, Ruiz-Morales JA, Villarreal-Garza C, et al. HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis. Euro J Neurol 2003; 10: 707–710. DOI: https://doi.org/10.1046/j.1468-1331.2003.00686.x
Shinomiya N, Nomura Y, Segawa M. A variant of childhood-onset myasthenia gravis: HLA typing and clinical characteristics in Japan. Clin Immunol 2004; 110: 154– 158. DOI: https://doi.org/10.1016/j.clim.2003.10.004
Donadi EA, Smith AG, Louzada-Junior P, Voltarelli JC, Nepom GT. HLA class I and class II profiles of patients presenting with Sydenham’s chorea. J Neurol 2000; 247(2):122-128.
Stanevicha V, Eglite J, Sochnevs A, Gardovska D, Zavadska D, Shantere R. HLA class II associations with rheumatic heart disease among clinically homogeneous patients in children in Latvia. Arthritis Res Ther 2003; 5(6):340-346. DOI: https://doi.org/10.1186/ar1000
Biggar RJ, Ng J, Kim N, Hisada M, Li HC, Cranston B, et al. Human leukocyt antigen concordance and the transmission risk via breast-feeding of human T cell lymphotropic virus type I. J Infect Dis 2006; 193(2): 277-282. DOI: https://doi.org/10.1086/498910
Manns A, Hanchard B, Morgan OS, Wilks R, Cranston B, Nam JM, et al. Human leukocyte antigen class II alleles associated with human T-cell lymphotropic vírus Type I infection and adult T-cell leukemia/lymphoma in a Black population. J Natl Cancer Inst 1998; 90(8): 617-621. DOI: https://doi.org/10.1093/jnci/90.8.617
Jeffery KJ, Usuku K, Matsumoto W, Matsumoto W, Taylor GP, Procter J, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci USA 1999; 96(7): 3848-3853. DOI: https://doi.org/10.1073/pnas.96.7.3848
Jeffery KJ, Siddiqui AA, Bunce M, Lloyd AL, Vine AM, Witkover AD, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 2000; 165: 7278-7284. DOI: https://doi.org/10.4049/jimmunol.165.12.7278
Suzuki Y. Host resistance in the brain against Toxoplasma gondii. J Infect Dis 2002;185(Suppl 1):S58–S65 DOI: https://doi.org/10.1086/337999
Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363(9425): 1965-1976. DOI: https://doi.org/10.1016/S0140-6736(04)16412-X
Mack DG, Johnson JJ, Roberts F, et al. HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol 1999; 29:1351–1358. DOI: https://doi.org/10.1016/S0020-7519(99)00152-6
Del Brutto OH, Granados G, Talamas O, Sotelo J, Gorodezky C. Genetic pattern of the HLA system: HLA A, B, C, DR, and DQ antigens in Mexican patients with parenchymal brain cysticercosis. Hum Biol 1991; 63(1):85-93.
Bompeixe EP, Costa SMCM, Arruda WO, Petzl-Erler ML. Lack of association between parenchymal neurocysticercosis and HLA Class I and Class II antigens. Genet. Mol Biol 1999; 22(1): 7-11.
Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002; 168(9):4772-4780. DOI: https://doi.org/10.4049/jimmunol.168.9.4772
Maier S, Geraghty DE, Weiss EH. Expression and regulation of HLA-G in human glioma cell lines. Transplant Proc 1999; 31(4): 1849-1853. DOI: https://doi.org/10.1016/S0041-1345(99)00186-4
Zagzag D, Salnikow K, Chiriboga L, Yee H, Lan L, Ali MA, et al. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab Invest 2005; 85(3): 328-341. DOI: https://doi.org/10.1038/labinvest.3700233
Machulla HK, Steinborn F, Schaaf A, Heidecke V, Rainov NG. Brain glioma and human leukocyte antigens (HLA): Is there an association? J Neurooncol 2001; 52(3): 253-261. DOI: https://doi.org/10.1023/A:1010612327647
Tang J, Shao W, Dorak MT, Li Y, Miike R, Lobashevsky E, et al. Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme. Cancer Epidemiol Biomarkers Prev 2005; 14(8): 2040-2044. DOI: https://doi.org/10.1158/1055-9965.EPI-05-0136
Corrias MV, Occhino M, Croce M, De Ambrosis A, Pistillo MP, Bocca P, et al. Lack of HLA-class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens 2001; 57(2): 110-117. DOI: https://doi.org/10.1034/j.1399-0039.2001.057002110.x
Raffaghello L, Prigione I, Airoldi I, et al. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett 2005; 228(1-2): 155-61. DOI: https://doi.org/10.1016/j.canlet.2004.11.064
Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, et al. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci 2004; 1028: 69-80. DOI: https://doi.org/10.1196/annals.1322.008
Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, et al. Expression of MHC class I, MHC class II, and cancer germ line antigens in neuroblastoma. Cancer Immunol Immunother 2005; 54(4): 400-406. DOI: https://doi.org/10.1007/s00262-004-0603-z
Renganathan R, Delanty N. Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed. Postgrad Med J 2003;79(928):78-80. DOI: https://doi.org/10.1136/pmj.79.928.78
Greenberg DA, Durner M, Shinnar S, Resor S, Rosenbaum D, Klotz I, et al. Association of HLA class II alleles in patients with juvenile myoclonic epilepsy compared with patients with other forms of adolescent-onset generalized epilepsy. Neurology 1996; 47(3):750-755. DOI: https://doi.org/10.1212/WNL.47.3.750
Le Hellard S, Neidhart E, Thomas P, Feingold J, Malafosse A, Tafti M. Lack of association between juvenile myoclonic epilepsy and HLA-DR13. Epilepsia 1999; 40(1): 117-119. DOI: https://doi.org/10.1111/j.1528-1157.1999.tb01999.x
Greenberg DA, Durner M, Keddache M, Shinnar S, Resor SR, Moshe SL, et al. Reproducibility and complications in gene searches: linkage on chromosome 6, heterogeneity, association, and maternal inheritance in juvenile myoclonic epilepsy. Am J Hum Genet 2000; 66(2):508-516. DOI: https://doi.org/10.1086/302763
